Table S2. MRM (Multiple reaction monitoring) parameters of the target compounds Compound name ChEBI Abbreviation ID molecular formula MW g/mole precursor ion (m/z) product ion (m/z) Dwell time CE (msec)
Table S2. Experiment parameters of Alice—Bob channel of OUTH-QDS illustrated in Fig. 4 of the main text.
Table S2. Concordance and agreement (Xxxxx’x kappa) between tuberculin skin testing and QuantiFERON-TB Gold In Tube, considering ≥5 mm a TST positive in non- BCG-vaccinated and ≥10 mm in BCG-vaccinated children.
Table S2. Age-adjusted Incidence Rates and Incidence Rate Ratios of Overall Type II Endometrial Cancer by Race/Ethnicity for 2004–2009 (Period 1) and 2010–2015 (Period 2) N IR (95% CI) IRR (95% CI) P value Overall
Table S2. Relative risk (RR) estimates and 95% confidence intervals (CI) of associations of heat wave days compared to non-heat wave days for ED visits for all 17 health outcomes. Heat waves were defined as periods of ≥ 2 consecutive days with temperature (T) or apparent temperature (AT) exceeding the 98th percentile using daily maximum (MAX), minimum (MIN), or average (AVG). The first day of the heat wave period was excluded from analyses. Outcome Heat Wave lag0 R.R. (95% C.I.) lag1 R.R. (95% C.I.) lag2 R.R. (95% C.I.) lag3 R.R. (95% C.I.) MAXT 1.00 (0.98, 1.01) 1.00 (0.98, 1.02) 1.00 (0.98, 1.02) 0.99 (0.97, 1.01) MINT 1.00 (0.99, 1.01) 1.00 (0.99, 1.01) 1.00 (0.99, 1.01) 1.00 (0.99, 1.01) All internal AVGT 0.99 (0.98, 1.00) 1.00 (0.98, 1.01) 1.00 (0.98, 1.01) 0.99 (0.98, 1.00)
Table S2. Inter-rater agreement a according to RSNA imaging classification for COVID-19 pneumonia diagnosis (continued).
Table S2. Zero-order and partial correlations between self-ratings, human judgments, and computer judgments for a subsample of participants (n = 1,919), for whom both human and computer judgments were available r ρ Correlations O C E A N O C E A N Human–computer (zero-order) 0.22 0.17 0.20 0.14 0.19 0.41 0.24 0.29 0.21 0.25 Human–computer (partial) 0.08 0.07 0.04NS 0.03NS 0.08 0.11 0.09 0.04NS 0.01NS 0.10 Self–human (zero-order) 0.30 0.26 0.37 0.29 0.29 0.61 0.39 0.55 0.49 0.40 Self–human (partial) 0.22 0.21 0.32 0.26 0.24 0.50 0.32 0.49 0.45 0.34 Self–computer (zero-order) 0.51 0.42 0.45 0.38 0.40 0.56 0.44 0.47 0.41 0.41 Self–computer (partial) 0.48 0.40 0.42 0.36 0.36 0.43 0.39 0.39 0.36 0.35 All correlations were significant at P < 0.01, unless otherwise stated. NS, not significant; r, raw correlations; ρ, correlations corrected for attenuation for self and humans’ ratings using Cronbach’s α reliability. Table S3. Summary of the external behaviors, behaviorally related traits, or life outcomes used in the study Variables Scales or sources Past findings Network size Number of Facebook friends (1) Network characteristics Facebook network 1) betweenness, 2) density, 3) transitivity, and 4) brokerage (2) Facebook activities Number of Facebook 1) status posts, 2) picture tags, 3) events, and 4) groups (1) Self-monitoring Self-Monitoring Scale, a 25-item scale assessing the degree to which one regulates self-presentation using situational cues (3) Impulsivity Barratt Impulsiveness Scale (BIS-11), a 30-item scale assessing general and specific dimensions of impulsiveness (5) Sensational interests The Sensational Interests Questionnaire, assessing 1) wholesome interests, 2) intellectual activities, 3) violent occultism, 4) militarism, and 5) credulousness (8) (4) (6, 7) (7, 8) Life satisfaction Satisfaction with Life Scale, a five-item scale assessing life satisfaction (9) (10) Depression Centre for Epidemiological Study Depression Scale (CES-D) (11) (12) Substance use Questionnaire assessing 1) alcohol consumption, 2) smoking behavior, and 3) drug use (13–15) Physical health Xxxxxxxxxx Inventory of Limbic Languidness (16), an inventory of respondents’ 1) experience of common physical symptoms, 2) recent days sick, 3) recent physician visits, and 4) recent days restricted due to illness Values Xxxxxxxx’x Values Survey, assessing 10 types of universal values, including 1) achievement, 2) benevolence, 3) conformity, 4) hedonism, 5) power, 6) security,
Table S2. Platelet P-selectin mean fluorescent intensity (MFI) under basal and stimulated conditions, in whole blood collected into either BD Vacutainers containing 0.109mol/l buffered sodium citrate or manual syringes preloaded with 0.109mol/l buffered sodium citrate. Syr: syringe driven aspiration; Vac: vacutainer driven aspiration; ADP: adenosine diphosphate. Values are shown as mean and 95% CI. Significance at P<.00125 (after Bonferroni correction).
Table S2. Comparisonsa of minimally-adjusted mean APC expressionb in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients (n = 104), by selected participant characteristics Proportional differencec (%) P-value Proportional differencec (%) P-value Proportional differencec (%) P-value 47 - 54 34 2,502 (2,148, 2,856) - 979 (817, 1,141) - 1,389 (1,157, 1,621) - 55 - 62 35 2,576 (2,224, 2,928) 3.0 1,040 (879, 1,201) 6.3 1,384 (1,153, 1,615) -0.3 63 - 75Sex Male 35 48 2,457 2,714 (2,106, 2,808) (2,338, 3,089) -1.8 - 0.88 1,026 1,074 (866, 1,186) (905, 1,242) 4.8 - 0.68 1,275 1,483 (1,045, 1,505) (1,261, 1,706) -8.2 - 0.51 Female 56 2,338 (1,990, 2,685) -13.9 0.15 966 (810, 1,122) -10.0 0.36 1,231 (1,026, 1,437) -17.0 0.10 Regulard use of aspirin No 64 2,586 (2,267, 2,904) - 1,078 (933, 1,223) - 1,350 (1,141, 1,560) - Yes 40 2,465 (2,221, 2,708) -4.7 0.58 977 (866, 1,088) -9.4 0.30 1,346 (1,186, 1,506) -0.3 0.98 Regulard use of other NSAID No 69 2,488 (2,152, 2,824) - 953 (801, 1,106) - 1,395 (1,175, 1,475) - YesCurrently smoke No 35 96 2,523 2,538 (2,293, 2,754) (2,349, 2,726) 1.4 - 0.87 1,048 1,029 (943, 1,152) (943, 1,115) 9.9 - 0.34 1,324 1,358 (1,172, 1,475) (1,234, 1,482) -5.2 - 0.61 Moderate 38 2,545 (2,204, 2,886) 4.9 1,027 (872, 1,183) 1.6 1,366 (1,143, 1,589) 8.4 High 27 2,518 (2,206, 2,830) 3.8 0.74 1,002 (859, 1,144) -1.0 0.91 1,375 (1,171, 1,580) 9.1 0.52 Body mass index (kg/m2) <25.0 22 2,477 (2,047, 2,907) - 986 (789, 1,182) - 1,360 (1,077, 1,642) - 25.0 - 29.9 43 2,575 (2,270, 2,880) 4.0 1,046 (907, 1,186) 6.1 1,379 (1,179, 1,579) 1.4 ≥30 Total energy, tertiles 1 39 34 2,461 2,813 (2,139, 2,782) (2,476, 3,149) 0.1 - 0.89 999 1,116 (852, 1,146) (960, 1,271) 1.4 - 0.99 1,307 1,548 (1,096, 1,518) (1,327, 1,768) -3.9 - 0.73 2 35 2,355 (2,017, 2,692) -16.3 937 (781, 1,094) -16.0 1,279 (1,058, 1,500) -17.4 3 Saturated fat, tertiles 1 35 34 2,388 2,756 (2,057, 2,719) (2,424, 3,089) -15.1 - 0.08 1,003 1,116 (850, 1,156) (961, 1,270) -10.1 - 0.31 1,230 1,482 (1,014, 1,447) (1,266, 1,698) -20.5 - 0.05 2 35 2,571 (2,238, 2,905 -6.7 974 (820, 1,129) -12.7 1,461 (1,244, 1,678) -1.4 3 Total fat, tertiles 1 35 34 2,203 2,602 (1,844, 2,562) (2,267, 2,938) -20.1 - 0.04 960 1,047 (794, 1,126) (891, 1,203) -14.0 - 0.17 1,094 1,406 (861, 1,327) (1,189, 1,623) -26.2 - 0.03 2 35 2,667 (2,335, 2,999) 2.5 1,027 (873, 1,182) -1.9 1,497 (1,283, 1,711) 6.5 3 35 2,256 (1,915, 2,596) -13.3 0.17 972 (814, 1,131) -7.1 0.52 1,132 (912, 1,352) -19.5 0.10 Totale vi...
Table S2. Detection of CLL recurrence by quantitative real-time PCR Months After End of CFAR Treatment Donor CLL HCDR3 (CT ) GAPDH (CT) ΔCT Δ(ΔCT) Fold Change CLL HCDR3 Detection 38 not detectable 18.7 ± 0.1 0.00 0 0 negative 51 37.48 25.4 ± 0.4 12.10 2.02 0.25 weak positive 56 26.4 ± 0.1 18.4 ± 0.2 8.02 -2.02 4.05 positive Table S2: Detection of CLL recurrence by quantitative real-time PCR. Cryopreserved MNCs from the CLL donor after treatment were analyzed by qPCR for the presence of CLL donor HCDR3 transcript. Each time point is calculated as months after end of CFAR treatment regimen. The CT , ΔCT, and Δ(ΔCT) of the qPCR reaction using the CLL donor HCDR3-specific probe and GAPDH probes were used to calculate the fold change in the CLL donor HCDR3 transcript relative to the GAPDH endogenous control. Data generated by X-J. Yan.
